Key result
Immunotherapy links to a ~1.5% cardiotoxicity rate in elderly patients regardless of prior cardiac history.
Why the study?
Despite the increasing use of cancer immunotherapy in aging populations, its safety regarding cardiotoxicity in elderly patients remains largely unknown.
Does immunotherapy cause cardiotoxicity in elderly patients (≥ 70 years) with solid tumors?
Population
195 patients ≥ 70 years old with solid tumours treated with immunotherapy
Design
Ambispective study
Authors
Loading...
Low cardiotoxicity rate with immunotherapy in elderly patients; hypothesis-generating and requires prospective confirmation before practice change.
Cohort (n=195)
No
Does immunotherapy cause cardiotoxicity in elderly patients (≥ 70 years) with solid tumors?
Immunotherapy appears to be safe regarding cardiotoxicity in elderly cancer patients, with a low event rate (1.54%) that does not significantly differ based on prior cardiac comorbidity.
Toribio-García et al. (2023) conducted a cohort in solid tumours (n=195). Immunotherapy was evaluated on Cardiotoxicity assessed using CTCAEv5.0 criteria. Immunotherapy was associated with a 1.54% rate of cardiotoxicity in elderly patients with solid tumors, with similar rates regardless of prior cardiac comorbidity.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: